OMIDRIA
Prevention of intraoperative miosis & postoperative pain in cataract surgery
ApprovedMarketed
Key Facts
Indication
Prevention of intraoperative miosis & postoperative pain in cataract surgery
Phase
Approved
Status
Marketed
Company
About Omeros Corporation
Omeros Corporation is a publicly traded biopharmaceutical company that leverages its expertise in immunology and inflammation to develop novel therapeutics. The company has built a portfolio around its commercial ophthalmology product, OMIDRIA, and is advancing multiple clinical-stage candidates, most notably its MASP-2 inhibitor narsoplimab for hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA). Omeros's strategy involves targeting both niche, high-need orphan diseases and larger commercial markets through its proprietary research platforms.
View full company profile